To facilitate the detection of proteins with overlapping molecular weights, PVDF membranes were physically cut according to the molecular weight markers.

The molecular weight and group name for the target protein and internal reference are presented below

Figure 2E


replicated 1
replicated 2
replicated 3
replicated 4
replicated 5
replicated 6
DSS − + + + +
AW1 − − 10 nM 100 nM 1 μM
ZO-1 (195 kDa) 180 kDa 130 kDa
Occludin (59 kDa) 70 kDa 55 kDa
Claudin-1 (22 kDa) 25 kDa 15 kDa
GAPDH (36 kDa) 40 kDa 35 kDa

Figure 3G


replicated 1
replicated 2
replicated 3
replicated 4
replicated 5
replicated 6
DSS − + + + +
AW1 − − 10 nM 100 nM 1 μM
ACT1 (72 kDa) 100 kDa 70 kDa
TRAF6 (58 kDa) 70 kDa 55 kDa
GAPDH (36 kDa) 36 kDa

Figure 3H


replicated 1
replicated 2
replicated 3
replicated 4
replicated 5
replicated 6
DSS − + + + +
AW1 − − 10 nM 100 nM 1 μM
P65 (65kDa) 70 kDa 55 kDa
p-P65 (65kDa) 70 kDa 55 kDa
IκBα (39kDa) 40 kDa 35 kDa
p-IκBα (39kDa) 40 kDa 35 kDa
GAPDH (36kDa) 35 kDa 25 kDa

Figure 3I


replicated 1
replicated 2
replicated 3
replicated 4
replicated 5
replicated 6
DSS − + + + +
AW1 − − 10 nM 100 nM 1 μM
Erk （42 kDa） 55 kDa 40 kDa
p-Erk （42 kDa） 55 kDa 40 kDa
JNK （46/54 kDa） 55 kDa 40 kDa
p-JNK （46/54 kDa） 55 kDa 40 kDa
P38 （40 kDa） 40 kDa 35 kDa
p-P38 （43 kDa） 55 kDa 40 kDa
GAPDH （36 kDa） 35 kDa

Figure 4I


replicated 1
replicated 2
replicated 3
replicated 4
replicated 5
replicated 6
Veh
Erastin
rhIL-17A
rhIL-17A+Ferr-1
ACSL4 (79 kDa) 100 kDa 70 kDa 55 kDa
xCT (35 kDa) 40 kDa 35 kDa 25 kDa
GPX4 (22 kDa) 25 kDa 15 kDa
PTGS2 (69 kDa) 100 kDa 70 kDa 55 kDa
GAPDH (36 kDa) 40 kDa 35 kDa

Figure 5G


replicated 1
replicated 2
replicated 3
replicated 4
replicated 5
replicated 6
rhIL-17A − + + + +
AW1(nM) − − 1 10 100
ACSL4 (79 kDa) 100 kDa 70 kDa 55 kDa
xCT (35 kDa) 40 kDa 35 kDa 25 kDa
GPX4 (22 kDa) 25 kDa 15 kDa
PTGS2 (69 kDa) 100 kDa 70 kDa 55 kDa
GAPDH (36 kDa) 40 kDa 35 kDa

Figure 5H


replicated 1
replicated 2
replicated 3
replicated 4
replicated 5
replicated 6
rhIL-17A − + + + +
AW1(nM) − − 1 10 100
ZO-1 (195 kDa) 180 kDa 130 kDa 100 kDa
Occludin (59 kDa) 70 kDa 55 kDa
Claudin-1 (22 kDa) 25 kDa 15 kDa
GAPDH (36 kDa) 40 kDa 35 kDa

Figure 5I


replicated 1
replicated 2
replicated 3
replicated 4
replicated 5
replicated 6
rhIL-17A − + + + +
AW1(nM) − − 1 10 100
ACT1 (72 kDa) 100 kDa 70 kDa
TRAF6 (58 kDa) 70 kDa 55 kDa
GAPDH (36 kDa) 40 kDa 36 kDa

Figure 5J


replicated 1
replicated 2
replicated 3
replicated 4
replicated 5
replicated 6
rhIL-17A − + + + +
AW1(nM) − − 1 10 100
P65 (65kDa) 70 kDa 55 kDa
p-P65 (65kDa) 70 kDa 55 kDa
IκBα (39kDa) 55 kDa 40 kDa
p-IκBα (39kDa) 40 kDa
GAPDH (36kDa) 35 kDa

Figure 5K


replicated 1
replicated 2
replicated 3
replicated 4
replicated 5
replicated 6
rhIL-17A − + + + +
AW1(nM) − − 1 10 100
Erk （42 kDa） 40 kDa 35 kDa 25 kDa
p-Erk （42 kDa） 40 kDa 35 kDa
JNK （46/54 kDa） 55 kDa 40 kDa
p-JNK （46/54 kDa） 55 kDa 40 kDa
P38 （40 kDa） 55 kDa 40 kDa
p-P38 （43 kDa） 55 kDa 40 kDa
GAPDH （36 kDa） 40 kDa 35 kDa

Figure 8G


replicated 1
replicated 2
replicated 3
replicated 4
replicated 5
replicated 6
DSS − + + + +
Brodalumab − − − + +
AW1(1 μM) − − + − +
ZO-1 (195 kDa) 180 kDa 130 kDa
Occludin (59 kDa) 70 kDa 55 kDa
Claudin-1 (22 kDa) 25 kDa 15 kDa
GAPDH (36 kDa) 40 kDa 35 kDa

Figure 8H


replicated 1
replicated 2
replicated 3
replicated 4
replicated 5
replicated 6
DSS − + + + +
Brodalumab − − − + +
AW1(1 μM) − − + − +
P65 (65kDa) 70 kDa 55 kDa
p-P65 (65kDa) 70 kDa 55 kDa
IκBα (39kDa) 40 kDa 35 kDa
p-IκBα (39kDa) 40 kDa 35 kDa
GAPDH (36kDa) 40 kDa 35 kDa


replicated 1
replicated 2
replicated 3
replicated 4
replicated 5
replicated 6
DSS − + + + +
Brodalumab − − − + +
AW1(1 μM) − − + − +
Erk （42 kDa） 55 kDa 40 kDa
p-Erk （42 kDa） 55 kDa 40 kDa
JNK （46/54 kDa） 55 kDa 40 kDa
p-JNK （46/54 kDa） 55 kDa 40 kDa
P38 （40 kDa） 40 kDa 35 kDa
p-P38 （43 kDa） 55 kDa 40 kDa
GAPDH （36 kDa） 40 kDa 35 kDa

Figure 9F


replicated 1
replicated 2
replicated 3
replicated 4
replicated 5
replicated 6
Veh rhIL-17A Ctrl rhIL-17A
sgNC
sgIL-17RA
ACSL4 (79 kDa) 100 kDa 70 kDa 55 kDa
xCT (35 kDa) 40 kDa 35 kDa 25 kDa
GPX4 (22 kDa) 25 kDa 15 kDa
PTGS2 (69 kDa) 100 kDa 70 kDa 55 kDa
GAPDH (36 kDa) 40 kDa 35 kDa

Figure 9H


replicated 1
replicated 2
replicated 3
replicated 4
replicated 5
replicated 6
DSS − + + + +
AW1 (100 nM) − − + − +
sgNC
sgIL-17RA
ZO-1 (195 kDa) 180 kDa 130 kDa 100 kDa
Occludin (59 kDa) 70 kDa 55 kDa
Claudin-1 (22 kDa) 25 kDa 15 kDa
GAPDH (36 kDa) 40 kDa 35 kDa

Figure 9I


replicated 1
replicated 2
replicated 3
replicated 4
replicated 5
replicated 6
DSS − + + + +
AW1 (100 nM) − − + − +
sgNC
sgIL-17RA
Erk （42 kDa） 55 kDa 40 kDa
p-Erk （42 kDa） 55 kDa 40 kDa
JNK （46/54 kDa） 55 kDa 40 kDa
p-JNK （46/54 kDa） 55 kDa 40 kDa
P38 （40 kDa） 40 kDa 35 kDa
p-P38 （43 kDa） 55 kDa 40 kDa
GAPDH （36 kDa） 40 kDa 35 kDa


replicated 1
replicated 2
replicated 3
replicated 4
replicated 5
replicated 6
DSS − + + + +
AW1 (100 nM) − − + − +
sgNC
sgIL-17RA
P65 (65kDa) 70 kDa 55 kDa
p-P65 (65kDa) 70 kDa 55 kDa
IκBα (39kDa) 55 kDa 40 kDa 35 kDa
p-IκBα (39kDa) 40 kDa 35 kDa
GAPDH (36kDa) 40 kDa 35 kDa

Figure S4I


replicated 1
replicated 2
replicated 3
replicated 4
replicated 5
replicated 6
DSS − + + + + +
Brodalumab − − − + − +
anti-IL-17A − − − − + −
AW1(1 μM) − − + − − +
ACSL4 (79 kDa) 100 kDa 70 kDa 55 kDa
xCT (35 kDa) 40 kDa 35 kDa 25 kDa
GPX4 (22 kDa) 25 kDa 15 kDa
PTGS2 (69 kDa) 100 kDa 70 kDa 55 kDa
GAPDH (36 kDa) 40 kDa 35 kDa